Osteosarcoma (OS) is a rare pediatric bone malignancy. Those who develop advanced
disease, often in the form of metastasis to the lung, experience poor five-year survival rates …

Osteosarcoma, a malignant bone tumor predominantly affecting children and adolescents,
presents significant therapeutic challenges, particularly in metastatic or recurrent cases …

Abstract Interleukin (IL)-12 is a protein that activates T cells and macrophages to kill tumor
cells. However, despite this cytokine showing strong antitumor activity in preclinical settings …

Osteosarcoma (OS) is the most common primary malignancy of the bone and has a high
propensity for local invasion and metastasis. Although combining surgery with …

Osteosarcoma is a primary malignant tumor that tends to threaten children and adolescents,
and the 5-year event-free survival rate has not improved significantly in the past three …

The osteosarcoma (OS) microenvironment is composed of tumor cells, immune cells, and
stromal tissue and is emerging as a pivotal player in OS development and progression …

The immune microenvironment extensively participates in tumorigenesis as well as
progression in osteosarcoma (OS). However, the landscape and dynamics of immune cells …

Osteosarcoma is the most frequent and aggressive bone tumor in children and adolescents,
with a long-term survival rate of 30%. Interleukin-12 (IL-12) is a potent cytokine that bridges …

Osteosarcoma, the most common malignant bone tumor in children and adolescents,
remains a complicated disease to treat; no new treatments have been developed in more …

Osteosarcoma (OS) is the most common primary malignancy of bone and patients with
metastatic disease or recurrences continue to have very poor outcomes. Unfortunately, little …